International Journal of Alzheimer’s Disease

International Journal of Alzheimer’s Disease / 2011 / Article

Research Article | Open Access

Volume 2011 |Article ID 171464 | 10 pages |

A Comparative Study of Five Mouse Models of Alzheimer's Disease: Cell Cycle Events Reveal New Insights into Neurons at Risk for Death

Academic Editor: Steven D. Edland
Received25 Apr 2011
Revised06 Jul 2011
Accepted11 Jul 2011
Published08 Sep 2011


Ectopic cell cycle events (CCEs) in postmitotic neurons link the neurodegenerative process in human Alzheimer's disease (AD) with the brain phenotype of transgenic mouse models with known familial AD genes. Most reports on the mouse models use the appearance of brain amyloid pathology as a key outcome measure. In the current paper, we focus on the induction of neurodegeneration using CCEs as markers for impending neuronal loss. We compare 5 mouse models of familial AD for the appearance of CCEs in subcortical regions—deep cerebellar nuclei, amygdala, locus coeruleus, hippocampus, and dorsal raphe. We find that the models differ in their CCE involvement as well as in the appearance of phosphorylated tau and amyloid deposition, suggesting that each model represents a different disease phenotype. Comparison with the pattern of neuron death in human AD suggests that each may represent a distinctly different disease model when used in preclinical trials.

1. Introduction

Alzheimer’s disease (AD) is a devastating late-onset neurodegenerative condition that affects many regions of the human brain. Although the most obvious disease symptoms involve the inability to form and store new memories, the neurological and psychiatric description of an individual with AD includes a wide range of symptoms such as depression, apathy, episodic behavioral outbursts, deteriorating executive functioning, and others. The biological substrates of these symptoms are only partially understood, but imaging and neuropathological studies have revealed important facets of their diverse and distributed nature. There is a clear loss of volume and pathologically visible degeneration in the brain’s memory centers, which include the entorhinal cortex, hippocampus, and basal forebrain nucleus. But there are also functional and structural abnormalities found in the locus coeruleus, dorsal raphe, cingulate gyrus, amygdala and prefrontal cortex as well as other cortical and subcortical regions [13]. Amyloid plaques and neurofibrillary tangles are the widely accepted biochemical signatures of AD, used to confirm the clinical diagnosis upon final neuropathological examination. These plaques and tangles are found in conjunction with significant and progressive neurodegeneration affecting both synapses and cell bodies. While the appearance of the abnormal deposits is disease specific, their anatomical locations in human AD mark only a subset of the brain regions that are identified as undergoing significant atrophy during the progress of the disease.

Recent work from our laboratory and many others has explored the use of abnormal neuronal cell cycle processes as an additional pathological marker of disease [411]. The timing and location of neuronal cell death in AD has been intimately associated with the unscheduled appearance of events related to mitotic cell division. Both cell cycle-related proteins and evidence of DNA replication have been found in neurons that are considered “at risk” for death. It is hypothesized that, although the neurons are able to initiate a true cell cycle and replicate most if not all of their genome, they are incapable of completing the process and are believed to die [12]. Using immunohistochemical analysis, cell cycle events (CCEs) have been identified in subcortical brain regions of individuals with AD as well as those with mild cognitive impairment (MCI—considered by many to be the clinical precursor of AD) [11]. In age-matched controls and in AD brain regions where neurons are not susceptible to death, cell cycle-related protein expression is significantly lower. This has led to the hypothesis that cell cycle events represent the first step of a process that leads to neuronal cell death in AD.

Significantly, these unexpected attempts by neurons to reenter a cell cycle provide one of the few homologies observed between mouse models of AD and the pathogenesis of the human condition. A number of different AD models have been created, most of which rely on transgenes encoding the gene for β-amyloid precursor protein (APP), presenilin-1 (PSEN1) or both [4]. Produced in a number of different laboratories, these models reproduce the plaque pathology of AD and lead to modest behavioral abnormalities. However, none produces the neurofibrillary tangles of AD or the severe behavioral changes that mark the end stages of the human disease. Other researchers have developed models of human tauopathies based on transgenes expressing disease causing variants of the microtubule-associated protein tau [13, 14]. Paradoxically, despite the fact that familial AD has not been significantly associated with tau (MAPT) mutations in humans, the tauopathy mouse models have been reasonably successful in reproducing many of the pathological characteristics of AD. With age, the brains of these animals display both tangles of hyperphosphorylated tau and progressive neurodegeneration in some cases [15]. Thus, MAPT models reproduce the tangles and degeneration but not the plaques, while the APP/PS1 models reproduce the Alzheimer’s plaques but not the associated tangles or neurodegeneration. From the standpoint of the plaques and tangles, therefore, the APP/PS1 mice are the better genocopies of AD while the MAPT mice are somewhat better phenocopies.

We have elected to focus on the pattern of neurodegeneration in APP transgenic mice in order to expand the characterization of this group of AD models, and we have used CCEs as outcome measures. Previously, where they have been studied in depth, the appearance of CCEs in many human disease models show an age-dependent increase in prevalence that often closely mimics the pattern of neuronal cell death in the human disease. For example, there is a significant correlation between the regional pattern of cell loss in human ataxia-telangiectasia and its mouse model [16]. The same is true for amyotrophic lateral sclerosis [17]. For human AD, the temporal and spatial appearance of CCEs in the R1.40 AD mouse model [1820] accurately recapitulate the anatomical progression of cell death in the human. In the current study, we expand the use of cell cycle markers as a benchmark of neuronal distress in the mouse. Our goal was to determine the phenotypic variability among the various mouse models of AD and to learn whether the similarities and differences observed are informative as to their relative fidelity to the human disease. We were particularly interested in exploring the involvement of the subcortical areas affected in AD since these regions typically receive less attention yet are likely to contribute significantly to the symptoms of AD. We focused our efforts on five of the many models available. We describe a pattern of selective neuronal vulnerability similar to human AD which is recapitulated in some, but not all of the five.

2. Material and Methods

2.1. Transgenic Mouse Models of AD

Five transgenic mouse models of familial AD were used in the current studies. In each model, amyloid plaques induced by APP develop at different ages. Detailed information about the mouse strains is summarized in Table 1. Most animals (R1.40 B6.129-Tg(APPSw)40Btla/J, APP/PS1 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J, APP8.9 B6.129S2-Tg(APP)8.9Btla/J and wild type) were housed at Rutgers University Animal Center. Brain tissues from the Tg2576 and Tg6799 mouse models were a generous gift from Dr. R. Vassar (Northwestern University). Three animals from the R1.40, Tg2576, and Tg6799 lines were examined for this study. Two each of the 8.9, APP/PS1 and wild-type strains were used.

Transgenic linesStrainApproachMutationPromoterAβ deposits (age of onset)Age of analysis (this study)

R1.40B6.129-Tg (APPSw) 40Btla/JYAC GenomicSwedish APPHuman APP14 months1 yr; 2 yrs
Tg2576B6 SJL-Tg (APPsw)cDNA (695)Swedish APPHamster PrP9–12 months9–11 months
Tg6799 (5xTg)B6SJL-Tg (APPSwFlLon, PSEN1*M146L*L286V) 6799Vas/JPronuclear coinjection : APP and PS1 transgenesSwedish, Florida and London APP & human PS1Murine Thy-13 months6 months
APP8.9B6.129S2-Tg (APP) 8.9Btla/JYAC GenomicWt huAPPHuman APPN/A; same as mouse APP expression14 months
APP/PS1B6.CgTg (APPswe, PSEN1dE9) 85Dbo/JcDNASwedish/human PS1Murine PrP6 months6-7 months

2.2. Histology

Animals were anesthetized with Avertin (0.02 cc/g body weight) and perfused through the heart with 0.1 M phosphate-buffered saline (PBS), followed by 4% paraformaldehyde in 0.1 M PBS solution. The brain was immediately removed from the skull and transferred to 4% paraformaldehyde at 4°C overnight. The brains were then cryoprotected by sinking in 30% sucrose in 0.1 M PBS at 4°C overnight. After cutting along the midline, the brains were embedded in OCT compound (Tissue-Tek). Cryostat sections were cut at 10 microns and air-dried on Superfrost/Plus glass slides overnight.

For hematoxylin staining, sections were washed in PBS with 0.25% Tween-20 and rinsed in PBS. They were exposed to hematoxylin for 45–60 sec then washed with double distilled water until clear. Sections were dehydrated through graded ethanol and two washes of xylene. VectaMount was used to mount slides.

2.3. Immunohistochemistry

A rabbit monoclonal antibody (Abcam, Cambridge, UK) to proliferating cell nuclear antigen (PCNA) was diluted 1 : 3000 in 10% goat serum/PBS blocking buffer before use. A rabbit polyclonal cyclin A antibody (Abcam, Cambridge, UK) was used at a working dilution of 1 : 500. The beta amyloid, 1–16 (6E10) mouse monoclonal antibody (Covance, Princeton, NJ), was used at a working dilution of 1 : 3000. The anti-PHF-tau antibody clone AT8 mouse monoclonal antibody (Thermo Scientific, Rockoff, IL) was used at a working dilution of 1 : 1000.

To perform fluorescent immunohistochemistry, sections were first rinsed twice in PBS, followed by pretreatment in Antigen Unmask Solution (Vector Laboratories, Burlingame, CA; working dilution 1 : 100) for 4-5 min at 95°C. After the slides had cooled in buffer for 10–20 min at room temperature, they were rinsed twice in double distilled H2O. For DAB staining, slides were subjected to an additional pretreatment step: 0.3% hydrogen peroxide in double distilled water for 30 min to remove endogenous peroxidase activity. Slides were then rinsed again in double distilled H2O followed by PBS. Subsequently, all sections were washed with PBS and incubated for 1 h at room temperature in 10% goat serum and 0.25% Tween-20 in PBS to block nonspecific binding. All primary antibodies, diluted in PBS containing 0.25% Tween-20 and 10% goat serum, were applied to sections and then incubated overnight at 4°C. After rinsing in three washes of PBS, they were incubated for 1 h with a secondary antibody, which was conjugated with fluorescent Alexa dyes (dilution, 1 : 500). The sections were rinsed with another three washes of PBS. Antifade with DAPI was applied before sealing the sections under a glass coverslip. For DAB staining, secondary antibody (1 : 500 dilution) was applied for 1 h at room temperature, washed three times in PBS, and incubated in Vectastain ABC Elite reagent (Vector Laboratories, Burlingame, CA) for thirty minutes. After three more PBS washes, slides were developed using diaminobenzidine (DAB), following the manufacturer’s protocol. Sections were dehydrated through double distilled water, graded ethanol, and washed twice in xylene. All sections were mounted in VectaMount under a glass coverslip. Control sections were subjected to the same staining procedure, except that primary antibody was omitted. Positive controls were obtained using cerebellar cortex of 15-day-old wild-type mice.

To analyze the immunocytochemical data in a more quantitative fashion, we developed a rating scale to rate the cell cycle, AT-8, and 6E10 markers. Scores were based only for their expression in the cell body of neurons. The values assigned to the rating scale were 0 (no staining or very little staining of cell cycle events), 1 (a few staining of cell cycle events 5–15%), 2 (low staining of cell cycle events, 15–30%), 3 (moderate staining of cell cycle events 30–50%), and 4 (>50% cell cycle events). Neuronal density was examined using hematoxylin staining.

3. Results

3.1. Mouse Models

We chose to study five different mouse models. The R1.40 YAC transgenic line contains a 650-kb yeast artificial chromosome (YAC) with the entire 400-kb huAPP gene modified with the Swedish mutation (K670N/M671L). R1.40 mice exhibit a preferential deposition of Aβ1-42, which results in the appearance of amyloid deposits in parietal cortex beginning at 13.5–14 months. In addition, the R1.40 cortex displays extensive neuritic abnormalities as evidenced by staining with APP, ubiquitin, neurofilament, and hyperphosphorylated tau antibodies [21, 22]. Tg2576 is a commonly used AD mouse model. An APP695 human cDNA transgene was used, with the Swedish (K670N/M671L) double mutation, under the regulation of the hamster PrP promoter. The mice develop β-amyloid deposits at 9–12 months [23]. Tg6799 is also known as the 5xTg transgenic mouse; it carries a single human APP cDNA with the Swedish K670N/M671L double mutation as well as the Florida I716V mutation, and the London V717I mutation. An additional human PSEN1 cDNA with M146L and L286V mutations was also inserted. Both cDNAs are driven by a mouse Thy-1 promoter. The mice show amyloid deposition as early as 2 months [24]. The APP/PS1 line was generated using a mouse prion protein promoter. The transgene includes a cDNA sequence encoding the human APP gene with the Swedish mutation as well as a PSEN1 cDNA transgene carrying the ΔE9 mutation (the sequence for exon 9 of PS1 is deleted). These were microinjected together resulting in the insertion of both APP and PSEN1 transgenes at a sinigle locus [25]. The APP8.9 line has a YAC genomic transgene similar to R1.40, but the transgene encodes a wild-type human APP gene instead of the Swedish mutation found in R1.40. The levels of APP transgene expression have been found to be similar to both normal levels of APP expression in humans as well as to the endogenous murine App gene. Although no plaque pathology has been described, the APP8.9 mouse should recapitulate the APP dosage imbalance found in Down Syndrome [26, 27].

3.2. Regional Differences

We used both DAB and fluorescent immunostaining of proliferating cell nuclear antigen (PCNA) to study the regional variations of CCEs in dorsal raphe, hippocampus, cerebellum, pons, amygdala, and locus coeruleus. PCNA is known to play an essential role in positioning the DNA polymerase in replication and repair of DNA [28]. Our results were confirmed using cyclin A, the activating subunit for several of the CDKs (cyclin-dependent kinases), which served as a second cell cycle marker. As the cyclin A results were comparable to those with PCNA, only the PCNA data are shown. The AT8 and 6E10 antibodies were used to identify neurofibrillary tangles and plaques, respectively. Immunostaining for tyrosine hydroxylase (TH) combined with their anatomical location was used to identify locus coeruleus neurons. Tryptophan hydroxylase (TpH) immunoreactivity plus anatomical location was used to identify the neurons of the dorsal raphe. The results from the locus coeruleus are illustrated in Figure 1. In 3 of the 5 models—APP/PS1, R1.40 and APP8.9 (Figure 1(b))—greater than 50% of these brainstem noradrenergic neurons were found to have immunocytochemical evidence of cell cycle activity. Tg2576 was much less affected and Tg6799 had evidence of only a few CCEs. No CCEs were detected in the wild-type locus coeruleus (Figure 1(c)). Despite the absence of cell cycle activity, Tg6799 scored the highest for phospho-tau staining, with greater than 50% of the neurons staining positive. Tg6799 was also the only model to show 6E10 staining in this region (Figure 1(d)); none of the other four AD models displayed any Aβ plaque deposition in the brainstem. A graphical summary of the CCEs and associated amyloid and tau staining patterns is shown in Figure 1(d).

The results from the dorsal raphe are shown in Figure 2. Most of the tryptophan hydroxylase immunoreactive neurons analyzed were from the region indicated by the box in Figure 2(a). Of the five models, R1.40 had the highest CCE rating (4), with greater than 50% of the neurons scoring positive for cell cycle staining (Figure 2(b)). APP8.9 had the second highest level of PCNA staining with moderate number of neurons positively stained. Age-matched wild-type mice showed virtually no cell cycle staining in this area (Figure 2(c)). Similar to our finding in the locus coeruleus, AT8 staining was variable and the dorsal raphe of the Tg6799 mouse model showed the highest levels AT8 staining. Across all genotypes, no correlation was observed between the CCE score and the presence or absence of AT8 or 6E10 immunoreactivity.

Our analysis of the amygdala was performed in sagittal sections, which makes the reliable identification of the specific subnuclei more difficult. To address this we divided the structure into three subregions as illustrated by the black boxes in Figure 3(a). The anterior region contained predominantly the anterior cortical amygdaloid nucleus, with small contributions of the nuclear ansae lenticularis and the medial and cortical amygdaloid nuclei; the middle region contained predominantly the posterolateral cortical, with lesser amounts of the anterior-lateral and central amygdaloid nuclei; the posterior region contained predominantly the posteromedial cortical amygdaloid nucleus with small contributions from the medial basal amygdaloid nucleus. Using this scheme, regional differences were found in the involvement of neuronal cell cycle events in the AD models. For all five models, the anterior portion of the amygdala demonstrated lower levels of cell cycle staining, while the medial and posterior portions showed higher levels of staining. Of the 5 transgenic models, R1.40 showed the highest level of immunoreactivity, with greater than 50% of the neurons in the posterior and medial portions of the amygdala staining positive for cell cycle events. Tg6799 had a slightly lower CCE score, followed by APP/PS1. Surprisingly, the wild-type mice showed modest levels of CCEs in the anterior and medial portions, but no CCEs in the posterior portions. Tg2576 and APP8.9 showed little staining or no staining in any of the three regions. In two models, R1.40 and APP/PS1, AT8 was distinctively higher in the posterior and medial regions. Other models had lower levels of AT8. Amyloid deposits in the amygdala, as revealed by 6E10 staining, were observed only in the anterior and medial regions of APP/PS1 mice.

All other regions of the CNS were substantially negative for cell cycle protein expression, as expected. The one exception to this was a small region of the ventral brainstem. In the pons and the more dorsal nucleus reticulari tegmentis pontis (NRTP), significant cell cycle protein expression was identified for all animals. Wild-type animals showed moderate levels of CCEs, with similar levels in the APP8.9 and Tg2576 APP/PS1 and Tg6799. The only exception to this pattern was found in the R1.40 model, which had low levels of CCEs in this region. The R1.40 showed high pontine levels of hyperphosphorylated tau, but low levels of 6E10-positive beta amyloid deposits. Tg6799 exhibited a very high level of 6E10 staining—at greater than 50%, the highest score of any of the models.

In addition to these results, there were observations of cell cycle staining that were more unexpected. For example, the deep nuclei of the cerebellum showed strong levels of CCEs in almost all the models (Figure 4). While AT8 and 6E10 staining was observed only in Tg6799 mice, four out of five transgenic models showed moderate CCE staining; R1.40 showed greater than 50% of the neurons positive for CCE staining. A more detailed analysis of the involvement of the cerebellar deep nuclei in the pathogenesis of AD is the subject of a newly published report [29].

The most unexpected finding, however, was in the hippocampal formation. CCEs have been reported in this region for two mouse models of AD, the PDAPP mouse and the R1.40 model [18]. In the current study, we did not choose to explore the PDAPP mice, but were able to replicate our findings in the R1.40 (Figure 5(b)). Both dentate granule neurons and pyramidal cells show cell cycle activity. Curiously, none of the other models we examined had evidence of cell cycle activity in this region. We observed no significant AT8 or 6E10 staining in the dentate gyrus or in the pyramidal cells of any of the mouse models (Figure 5(d)).

4. Discussion

Transgenic mouse models have long been used to study the molecular mechanisms of disease. To be considered useful, such models must recapitulate the human disease in as many ways as possible, and by this criterion the mouse models of AD have been at least partially successful. No wild-type mouse has been reported to naturally develop amyloid plaques, neurofibrillary tangles, or an Alzheimer’s-like loss of neurons in any brain region. By contrast, mouse lines expressing APP and/or PSEN1 transgenes with AD-related mutations display an age-related appearance of β-amyloid plaques and hyperphosphorylated tau [30]. Behavioral and neurophysiological abnormalities have also been observed in some transgenic models, as well as neurophysiological defects, inflammation, and occasionally a decrease in the numbers of CA1 pyramidal neurons [31]. Impressively, the YAC R.140 model shows a regional pattern of cerebral and vascular amyloid deposits along with reactive astrocytes and microglia that is consistent with the pattern of these events in human AD. In the end, however, the reproduction of the human disease has been incomplete in all of these lines. No neurofibrillary tangles are found; neurodegeneration is limited even in the best models; and the behavioral changes are mild compared to those observed in humans with mid- to late-stage Alzheimer’s disease. Also, because most successful APP-expressing mouse lines require highly elevated levels of transgene expression to form plaques, the use of plaque deposition as the major outcome measure for evaluating the effectiveness of the models represents somewhat of a self-fulfilling prophecy [32]. This raises concerns that the effectiveness of the current APP-based AD mouse models might be compromised.

One of these concerns that we attempt to address here is the poor reproduction in the mouse of the neuronal cell death found in AD. In human AD, there is a massive degeneration of neurons and this is observed in a pattern with pronounced temporal and regional variability [33]. While the reasons for the discordance between mouse and human phenotypes are unknown, if CCEs are used in place of actual neuronal cell loss as an index of neurodegeneration, our previous studies of the R1.40 model suggest a remarkably faithful replication of the progression of neuronal cell death in human AD. What remains unknown is why, if CCEs are correlated with neuronal cell death, the subsequent death of neurons is not immediate. Indeed, studies in both mouse and human suggest that cell cycling and cell death can be months apart [19, 34].

To the appearance of cell cycle events, we add the correlation with more traditional neuropathological indicators of Alzheimer’s disease. Our findings show that β-amyloid deposits appear in several subcortical regions—not just in the R1.40 mouse [34], but in most models. The anatomical distribution of the deposits, however, is not identical. β-amyloid deposition appears in some but not all of the structures studied and some but not all of the models stain with the AT8 phospho-tau antibody. Based on the models we examined, it would appear that amyloid deposits and tau expression levels showed region- and model-specificity and thus cautions should apply.

In this study, we have expanded the range of biological responses in the 5 different AD mouse models to include cell cycle events (CCEs) as direct cell-autonomous indices of neuronal distress. Since CCEs have been observed in both the human AD brain and in the analogous regions of certain AD mouse models, characterizing CCE expression patterns provides a logical and independent outcome measure for the study of neuronal death process in human AD. It is significant, therefore, that the results reported here demonstrate clear differences among the mouse models examined in the pattern of CCE expression. We find a high level of CCEs in the brain stem of all 5 models, including the pons, locus coeruleus, dorsal raphe, and deep nuclei of the cerebellum. The consistent appearance of CCEs in these more caudal regions of the CNS despite differing transgene properties and β-amyloid and tau pathologies is significant. It implies that the existence of neuronal stress in metencephalic and myelencephalic regions in familial AD may represent a central feature of disease pathogenesis. This is consistent with previous suggestions arising from entirely different lines of evidence. Immunocytochemical and biochemical techniques revealed that cells produced from a locus coeruleus-derived cell line, but not hippocampal and cortical neurons, exhibited beta-amyloid accumulation and concentrate β-secretase at process terminals [35]. In the same study, it was shown that intracellular Aβ plaques can become extracellular when neurites degenerate, which leads to additional accumulation and extracellular aggregation. In a different domain, the locus coeruleus has been proposed to play a role in brain inflammatory processes, such as those seen in AD [36, 37]. More recently, Braak and Tredici, using tau phosphorylation as an index, also report very early disease pathology in the locus coeruleus [38].

The pattern of CCEs in the amygdala suggests internal variations in AD pathology in this structure such as is seen in the cortex. In several AD models, the posterior and central amygdaloid nuclei showed stronger levels of CCE expression when compared to more anterior amygdaloid neurons, suggesting a common impact of APP transgene expression in this region. This variation is not apparent in the 6E10 or AT8 staining suggesting that specific neuroanatomical phenotypes may be uncovered when CCE markers are used. Our findings in the AD mouse models are consistent with the well-documented involvement of the structure in human AD pathology [3941]. These studies have shown that significant numbers of neurons in the amygdala die during the early stages of AD. Although there is less information available on the regional variability within the amygdala, attempts have been made to use degeneration in this structure to detect the onset of AD [34, 42].

The R1.40 model showed the strongest staining for CCEs in most subcortical regions and was the only model in the current study to show significant CCE expression in the hippocampal region. The absence of CCE expression in the 4 other AD models we studied is noteworthy, albeit without explanation. Nearly all of the models we studied have been shown to have deficits in behavioral tasks that are known to involve the hippocampus. This discordance between function and pyramidal cell body neuropathology suggests several hypotheses, none of which are mutually exclusive. Perhaps the behavioral changes are due to synaptic loss or atrophy [43], but the cell body, as seen through the appearance of CCEs or neuronal cell death, remains largely unaffected. A related hypothesis is that the transgene-dependent excess of Aβ at the synapse is the cause of the behavioral and physiological changes. Aβ, especially the lower molecular weight form, is recognized as having a neuromodulatory function [44]. Finally, as the ages of the animals we examined were mostly one year or less, it is also possible that the disease process in the hippocampus was not sufficiently advanced at the time of perfusion.

All of these alternatives are consistent with the proposal that Alzheimer’s begins as a synaptic disease. What is unknown at present is whether these synaptic problems precede the CCEs. This would appear to be the situation in hippocampus where slices, isolated in vitro, show impaired LTP [45]; whether this accounts for all of the behavioral changes or whether some might be due to the aberrant cell cycle activity is unknown at this time.

Although no single mouse model provides a complete recapitulation of human AD, based on the regions we examined, the YAC R1.40 would appear to be the most reliable model, especially when using CCEs as an outcome measure. One possible explanation for R1.40’s strong fidelity as a model is the close reproduction of the pattern of transgenic APP expression to that found in human. This in turn is most likely due to the method used to insert the mutant gene [21, 22]. With the exception of APP8.9, the other transgenes encode a single splice form of the human APP cDNA. The R1.40 mouse model carries the entire human APP gene, including all introns and all 3′ and 5′ regulatory elements within 30–50 kb of the coding sequence. This allows for a more faithful temporal and spatial expression pattern, possibly contributing to a more faithful reproduction of the human disease.

5. Conclusions

We have shown here that CCE markers are a reasonable way of studying AD mouse model fidelity to human AD. Since no transgenic mouse model is able to perfectly capture the complexities of the human AD pathology, using several phenotypic markers to study the effects of transgene insertions is well advised. Distinguishing the role of species differences and the effects of transgenes in AD pathogenesis through rigorous characterization of mouse models and AD will be important to uncovering the mechanisms of AD pathogenesis and lead to the more rapid identification of useful therapeutic targets.


L. Li and T. Cheung contributed equally to the work.


  1. C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chui, “Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases,” Archives of Neurology, vol. 60, no. 3, pp. 337–341, 2003. View at: Publisher Site | Google Scholar
  2. R. M. Zweig, C. A. Ross, J. C. Hedreen et al., “Neuropathology of aminergic nuclei in Alzheimer's disease,” Progress in Clinical and Biological Research, vol. 317, pp. 353–365, 1989. View at: Google Scholar
  3. A. Brun and E. Englund, “Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading,” Histopathology, vol. 5, no. 5, pp. 549–564, 1981. View at: Google Scholar
  4. J. Götz and L. M. Ittner, “Animal models of Alzheimer's disease and frontotemporal dementia,” Nature Reviews Neuroscience, vol. 9, no. 7, pp. 532–544, 2008. View at: Publisher Site | Google Scholar
  5. T. Arendt, L. Rödel, U. Gärtner, and M. Holzer, “Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease,” NeuroReport, vol. 7, no. 18, pp. 3047–3049, 1996. View at: Google Scholar
  6. J. Busser, D. S. Geldmacher, and K. Herrup, “Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain,” Journal of Neuroscience, vol. 18, no. 8, pp. 2801–2807, 1998. View at: Google Scholar
  7. A. McShea, P. L. R. Harris, K. R. Webster, A. F. Wahl, and M. A. Smith, “Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease,” American Journal of Pathology, vol. 150, no. 6, pp. 1933–1939, 1997. View at: Google Scholar
  8. Z. Nagy, M. M. Esiri, A. M. Cato, and A. D. Smith, “Cell cycle markers in the hippocampus in Alzheimer's disease,” Acta Neuropathologica, vol. 94, no. 1, pp. 6–15, 1997. View at: Publisher Site | Google Scholar
  9. T. W. Smith and C. F. Lippa, “Ki-67 immunoreactivity in Alzheimer's disease and other neurodegenerative disorders,” Journal of Neuropathology and Experimental Neurology, vol. 54, no. 3, pp. 297–303, 1995. View at: Google Scholar
  10. Y. Yang, D. S. Geldmacher, and K. Herrup, “DNA replication precedes neuronal cell death in Alzheimer's disease,” Journal of Neuroscience, vol. 21, no. 8, pp. 2661–2668, 2001. View at: Google Scholar
  11. Y. Yang, E. J. Mufson, and K. Herrup, “Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease,” Journal of Neuroscience, vol. 23, no. 7, pp. 2557–2563, 2003. View at: Google Scholar
  12. K. Herrup and Y. Yang, “Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?” Nature Reviews Neuroscience, vol. 8, no. 5, pp. 368–378, 2007. View at: Publisher Site | Google Scholar
  13. D. Games, M. Buttini, D. Kobayashi, D. Schenk, and P. Seubert, “Mice as models: transgenic approaches and Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 9, supplement 3, pp. 133–149, 2006. View at: Google Scholar
  14. V. M. Y. Lee, T. K. Kenyon, and J. Q. Trojanowski, “Transgenic animal models of tauopathies,” Biochimica et Biophysica Acta, vol. 1739, no. 2-3, pp. 251–259, 2005. View at: Publisher Site | Google Scholar
  15. C. Ballatore, V. M. Y. Lee, and J. Q. Trojanowski, “Tau-mediated neurodegeneration in Alzheimer's disease and related disorders,” Nature Reviews Neuroscience, vol. 8, no. 9, pp. 663–672, 2007. View at: Publisher Site | Google Scholar
  16. Y. Yang and K. Herrup, “Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism,” Journal of Neuroscience, vol. 25, no. 10, pp. 2522–2529, 2005. View at: Publisher Site | Google Scholar
  17. M. D. Nguyen, M. Boudreau, J. Kriz, S. Couillard-Després, D. R. Kaplan, and J. P. Julien, “Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1,” Journal of Neuroscience, vol. 23, no. 6, pp. 2131–2140, 2003. View at: Google Scholar
  18. Y. Yang, N. H. Varvel, B. T. Lamb, and K. Herrup, “Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models,” Journal of Neuroscience, vol. 26, no. 3, pp. 775–784, 2006. View at: Publisher Site | Google Scholar
  19. N. H. Varvel, K. Bhaskar, M. Z. Kounnas et al., “NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease,” Journal of Clinical Investigation, vol. 119, no. 12, pp. 3692–3702, 2009. View at: Publisher Site | Google Scholar
  20. N. H. Varvel, K. Bhaskar, A. R. Patil, S. W. Pimplikar, K. Herrup, and B. T. Lamb, “Aβ oligomers induce neuronal cell cycle events in Alzheimer's disease,” Journal of Neuroscience, vol. 28, no. 43, pp. 10786–10793, 2008. View at: Publisher Site | Google Scholar
  21. B. T. Lamb, L. M. Call, H. H. Slunt et al., “Altered metabolism of familial Alzheimer's disease linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice,” Human Molecular Genetics, vol. 6, no. 9, pp. 1535–1541, 1997. View at: Publisher Site | Google Scholar
  22. L. S. Kulnane and B. T. Lamb, “Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice,” Neurobiology of Disease, vol. 8, no. 6, pp. 982–992, 2001. View at: Publisher Site | Google Scholar
  23. K. Hsiao, P. Chapman, S. Nilsen et al., “Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice,” Science, vol. 274, no. 5284, pp. 99–102, 1996. View at: Publisher Site | Google Scholar
  24. H. Oakley, S. L. Cole, S. Logan et al., “Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation,” Journal of Neuroscience, vol. 26, no. 40, pp. 10129–10140, 2006. View at: Publisher Site | Google Scholar
  25. J. L. Jankowsky, D. J. Fadale, J. Anderson et al., “Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase,” Human Molecular Genetics, vol. 13, no. 2, pp. 159–170, 2004. View at: Publisher Site | Google Scholar
  26. B. T. Lamb, S. S. Sisodia, A. M. Lawler et al., “Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice,” Nature Genetics, vol. 5, no. 1, pp. 22–30, 1993. View at: Publisher Site | Google Scholar
  27. A. Alpár, U. Ueberham, M. K. Brückner, T. Arendt, and U. Gärtner, “The expression of wild-type human amyloid precursor protein affects the dendritic phenotype of neocortical pyramidal neurons in transgenic mice,” International Journal of Developmental Neuroscience, vol. 24, no. 2-3, pp. 133–140, 2006. View at: Publisher Site | Google Scholar
  28. Z. Kelman, “PCNA: structure, functions and interactions,” Oncogene, vol. 14, no. 6, pp. 629–640, 1997. View at: Google Scholar
  29. J. Chen, M. L. Cohen, A. J. Lerner, Y. Yang, and K. Herrup, “DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer's disease,” Molecular Neurodegeneration, vol. 5, article 60, 2010. View at: Publisher Site | Google Scholar
  30. K. Duff, “Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis,” Biochemical Society Symposium, vol. 67, pp. 195–202, 2001. View at: Google Scholar
  31. J. Götz, J. R. Streffer, D. David et al., “Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy,” Molecular Psychiatry, vol. 9, no. 7, pp. 664–683, 2004. View at: Google Scholar
  32. T. L. Spires and B. T. Hyman, “Transgenic models of Alzheimer's disease: learning from animals,” NeuroRx, vol. 2, no. 3, pp. 423–437, 2005. View at: Publisher Site | Google Scholar
  33. K. Duff and F. Suleman, “Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?” Briefings in Functional Genomics & Proteomics, vol. 3, no. 1, pp. 47–59, 2004. View at: Google Scholar
  34. M. Basso, J. Yang, L. Warren et al., “Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease,” Psychiatry Research—Neuroimaging, vol. 146, no. 3, pp. 251–261, 2006. View at: Publisher Site | Google Scholar
  35. Z. Muresan and V. Muresan, “Seeding neuritic plaques from the distance: a possible role for brainstem neurons in the development of Alzheimer's disease pathology,” Neurodegenerative Diseases, vol. 5, no. 3-4, pp. 250–253, 2008. View at: Publisher Site | Google Scholar
  36. M. T. Heneka, E. Galea, V. Gavriluyk et al., “Noradrenergic depletion potentiates β-amyloid-induced cortical inflammation: implications for Alzheimer's disease,” Journal of Neuroscience, vol. 22, no. 7, pp. 2434–2442, 2002. View at: Google Scholar
  37. M. T. Heneka, M. Ramanathan, A. H. Jacobs et al., “Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice,” Journal of Neuroscience, vol. 26, no. 5, pp. 1343–1354, 2006. View at: Publisher Site | Google Scholar
  38. H. Braak and K. Del Tredici, “The pathological process underlying Alzheimer's disease in individuals under thirty,” Acta Neuropathologica, vol. 121, no. 2, pp. 171–181, 2011. View at: Google Scholar
  39. S. A. Scott, S. T. DeKosky, D. L. Sparks, C. A. Knox, and S. W. Scheff, “Amygdala cell loss and atrophy in Alzheimer's disease,” Annals of Neurology, vol. 32, no. 4, pp. 555–563, 1992. View at: Publisher Site | Google Scholar
  40. J. W. Unger, L. W. Lapham, T. H. McNeill, T. A. Eskin, and R. W. Hamill, “The amygdala in Alzheimer's disease: neuropathology and Alz 50 immunoreactivity,” Neurobiology of Aging, vol. 12, no. 5, pp. 389–399, 1991. View at: Publisher Site | Google Scholar
  41. T. Matsuzawa, T. Hishinuma, H. Matsui et al., “Severe atrophy of amygdala and hippocampus in both Alzheimer's disease and multi-infarct dementia,” Science Reports of the Research Institutes Tohoku University C, vol. 37, no. 1–4, pp. 23–25, 1990. View at: Google Scholar
  42. C. A. Cuenod, A. Denys, J. L. Michot et al., “Amygdala atrophy in Alzheimer's disease: an in vivo magnetic resonance imaging study,” Archives of Neurology, vol. 50, no. 9, pp. 941–945, 1993. View at: Google Scholar
  43. D. J. Selkoe, “Alzheimer's disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002. View at: Publisher Site | Google Scholar
  44. G. M. Shankar, S. Li, T. H. Mehta et al., “Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory,” Nature Medicine, vol. 14, no. 8, pp. 837–842, 2008. View at: Publisher Site | Google Scholar
  45. Q. S. Chen, B. L. Kagan, Y. Hirakura, and C. W. Xie, “Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides,” Journal of Neuroscience Research, vol. 60, no. 1, pp. 65–72, 2000. View at: Google Scholar

Copyright © 2011 Luming Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

3760 Views | 1561 Downloads | 13 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.